公司名稱: 金活醫藥集團有限公司 呈交日期: 2026年2月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | 本月 ...

为保障交易有序推进，备忘录明确约定，金活医药(BVI)将在备忘录签署后的五个工作日内，向卖方支 付332.184万港元作为交易按金，但因该按金占集团相关财务指标比例不足5%，故此次备忘录签署未构 成香港联交所上市规则项下的须予公布交易。后续，集团表示将依据交易进展及时履行信息披露义务。 就此次潜在收购，金活医药主席兼执行董事赵利生先生表示："此次潜在收购是集团完善大健康产业链 布局、深化全球化战略的关键举措。目标公司拥有成熟的生产体系、享誉海内外的知名品牌及优质的固 定资产，与集团在全国34省市及港澳地区构建的立体化分销网络高度契合。未来，集团将通过深度资源 整合，借助自身全渠道供应链优势放大目标品牌影响力，充分释放协同效应，为集团可持续增长注入多 元动力，进一步巩固在医药大健康领域的综合竞争力。" 资料显示，金活医药深耕医药健康领域三十年，并在欧洲设立了Innopharm等分支机构，积极布局全球 市场。集团已构建起覆盖上下游的完善供应链体系，成功代理京都念慈菴蜜炼川贝枇杷膏、喇叭牌正露 丸、金活依马打正红花油等多个知名医药品及保健品品牌，业务范围全面覆盖内地34个省市、港澳地区 及主流线上渠道，稳居中国药品 ...

受签立买卖协议及当中所述调整机制(如有)所规限，总代价须包括：(i)基本购买价6643.68万港元，其中 4150万港元涉及目标公司的相关业务及生产设备(车辆除外)，2493.68万港元涉及地产物业;(ii)目标公司 设备(不包括任何车辆)于完成时的净账面值;及(iii)于完成时的营运资金净额(即应收账款与存货总和减应 付账款)，惟须根据依照香港财务报告准则编制的经审核账目作出完成后调整。自签订谅解备忘录起五 个营业日内，金活医药(BVI)将向拟定卖方支付按金约332.18万港元。 公告称，目标公司为一间于香港注册成立的公司，主要从事药品生产及销售，并于地产物业内进行营 运。董事认为，倘建议收购事项得以落实，将使集团能够扩大其于香港医药行业的版图，获得包括地产 物业在内的宝贵制造资产，并透过产品分销及营运规模的协同效应，促进集团的海内外业务发展。 金活医药集团(01110)公布，于2026年1月22日，公司的全资附属公司金活医药(BVI)就建议收购事项与拟 定卖方及担保人订立谅解备忘录。预计代价将以现金支付。担保人同意就拟定卖方履行其于谅解备忘录 项下的责任提供担保。 ...

受签立买卖协议及当中所述调整机制(如有)所规限，总代价须包括：(i)基本购买价6643.68万港元，其中 4150万港元涉及目标公司的相关业务及生产设备(车辆除外)，2493.68万港元涉及地产物业;(ii)目标公司 设备(不包括任何车辆)于完成时的净账面值;及(iii)于完成时的营运资金净额(即应收账款与存货总和减应 付账款)，惟须根据依照香港财务报告准则编制的经审核账目作出完成后调整。自签订谅解备忘录起五 个营业日内，金活医药(BVI)将向拟定卖方支付按金约332.18万港元。 智通财经APP讯，金活医药集团(01110)公布，于2026年1月22日，公司的全资附属公司金活医药(BVI)就 建议收购事项与拟定卖方及担保人订立谅解备忘录。预计代价将以现金支付。担保人同意就拟定卖方履 行其于谅解备忘录项下的责任提供担保。 公告称，目标公司为一间于香港注册成立的公司，主要从事药品生产及销售，并于地产物业内进行营 运。董事认为，倘建议收购事项得以落实，将使集团能够扩大其于香港医药行业的版图，获得包括地产 物业在内的宝贵制造资产，并透过产品分销及营运规模的协同效应，促进集团的海内外业务发展。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願公告 有關建議收購事項之諒解備忘錄 本公告由金活醫藥集團有限公司自願作出。 董事會欣然宣佈，於二零二六年一月二十二日（交易時段後），本公司之全資附 屬公司金活醫藥(BVI)就建議收購事項與擬定賣方及擔保人訂立諒解備忘錄。目 標公司主要從事藥品生產及銷售並持有地產物業。預計代價將以現金支付。擔 保人同意就擬定賣方履行其於諒解備忘錄項下之責任提供擔保。 自簽訂諒解備忘錄起五個營業日內，金活醫藥(BVI)將向擬定賣方支付按金 3,321,840港元。由於就支付按金而言，上市規則項下之相關百分比率均低於 5%，故訂立諒解備忘錄並不構成上市規則第十四章項下本公司之須予公佈交 易。 倘建議收購事項得以落實，則可能構成上市規則第十四章項下本公司之須予披 露交易。 董事會謹此強調，於本公告日期，金活醫藥(BVI)並未就建議收購事項與任何人 士訂立具法律約束力之協議（諒解備忘錄內有關（其中包括）按金、盡職審查、 排他 ...

Core Insights - The article highlights the successful integration of modern agriculture and global supply chains, particularly focusing on the winter availability of strawberries from Dandong, China, and cherries (referred to as "车厘子") from Chile, which cater to the Chinese New Year market demand [1][2][3] Group 1: Seasonal Availability - Strawberries, traditionally a spring fruit, are now available year-round due to advanced cultivation techniques, with Dandong farmers harvesting multiple crops from August to March [2][3] - Chilean cherries are harvested from November to February, coinciding with the winter season in the Northern Hemisphere, allowing for a continuous supply of fresh cherries during the Chinese New Year [3] Group 2: Preservation Techniques - Dandong strawberries maintain freshness through rapid cooling and cold chain logistics, with a two-hour window for pre-cooling after harvest, ensuring delivery within 48 hours [4] - Chilean cherries utilize a combination of quick cooling and modified atmosphere packaging to extend shelf life, with cherries entering ice water within 3-4 hours post-harvest [4] Group 3: Food Safety Measures - Dandong strawberries are cultivated using green farming techniques, including organic fertilizers and physical pest control, ensuring a safe product for consumers [5] - Chilean cherries adhere to strict export standards, with quality checks at both the source and upon arrival in China, providing a dual layer of safety for consumers [6] Group 4: Financial Support for Agriculture - Guangfa Bank has introduced innovative financial products to support the strawberry and cherry industries, including a specialized loan program for strawberry farmers in Dandong, with a maximum credit limit of 300,000 yuan [7] - The bank's services extend to the logistics and sales chain for Chilean cherries, facilitating timely financing for international procurement and domestic logistics [7] Group 5: Conclusion - The article emphasizes the collaborative efforts of farmers, technology, and financial institutions in ensuring the availability of fresh strawberries and cherries, showcasing a model of modern agricultural practices [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金活醫藥集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1 ...

Group 1 - The "Annual Outstanding Healthcare Enterprises" award recognizes companies in the Chinese healthcare industry that excel in innovation, technological leadership, market influence, social value, and sustainable development [4] - The award winners include Alibaba Health (00241.HK), Anxuyuan, Baize Medical (02609.HK), Gushengtang (02273.HK), Haijia Medical (06078.HK), Jinhua Medical Group (01110.HK), Kangchen Pharmaceutical (01681.HK), Ping An Good Doctor (01833.HK), Weitai Medical-B (02235.HK), and Xinwei Medical-B (06609.HK) [1] - The selection process involved quantitative data analysis and an expert review panel to determine the final results [4] Group 2 - The "Jin Ge Award" aims to create a reference for the investment community by highlighting the most valuable listed companies and unicorns in China [4] - The evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4]

Group 1 - The photovoltaic sector experienced a significant intraday surge, with the photovoltaic industry index rising by 2.06% as of 14:03, led by stocks such as Roboteam and Kstar [1] - The "anti-involution" efforts in the photovoltaic industry have begun to show results, with prices in the photovoltaic supply chain starting to recover and corporate profits improving, particularly in the upstream polysilicon segment [1] - In December, domestic polysilicon production decreased by 0.96% month-on-month, while wafer, cell, and module production saw declines of 15.95%, 12.61%, and 13.58% respectively, indicating a trend of reduced production across multiple segments of the photovoltaic supply chain [1] Group 2 - Industry insiders attribute the continued decline in production across multiple segments in December to insufficient terminal demand, suggesting that the effects of "anti-involution" will lead to a gradual price recovery in the photovoltaic industry by 2026 [1] - CITIC Construction Investment Securities noted that price control measures have led to price increases in the main supply chain since July, with the polysilicon segment returning to profitability in Q3, although there remains significant inventory pressure of approximately 460,000 tons across the industry [1] - The overall expectation is that the "anti-involution" policy will help restore profitability to reasonable levels across various segments of the photovoltaic supply chain [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 金活醫藥集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | ...